Introduction {#s1}
============

Breast cancer, a leading cause of cancer death in women, is recognized to be a molecularly heterogeneous disease. Markers such as estrogen receptor (ER), progesterone receptor (PR) and ERBB2/HER2 are used for prognostication, and to stratify patients for appropriately targeted therapies [@pone.0006146-Subramaniam1].

More recently, DNA microarray studies have suggested a refined classification of breast cancer, distinguishing five major subtypes based on different patterns of gene expression, underlying DNA copy number alterations (CNAs), and associated clinical outcomes [@pone.0006146-Perou1]--[@pone.0006146-Chin1]. Luminal subtypes A and B are ER positive and share expression markers with the luminal epithelial layer of cells lining normal breast ducts. Luminal-A tumors are genetically simple (1q/16p gain) and are associated with favorable outcome, while luminal-B tumors exhibit high proliferation rates, frequent DNA amplification (e.g. 8q24/*MYC*), and less favorable prognosis. Basal-like tumors share expression markers with the underlying basal (myoepithelial) layer of normal breast ducts, are ER negative, exhibit frequent chromosome segmental gains/losses, and are associated with poor outcome in most studies. The ERBB2 subtype is associated with expression of genes co-amplified with *ERBB2* (encoding HER2) on chromosome cytoband 17q12, and the normal-like subtype shares expression patterns with normal breast tissue.

Breast cancer cell lines have been used widely to investigate breast cancer pathobiology, and to screen and characterize new therapeutics [@pone.0006146-Lacroix1], [@pone.0006146-VargoGogola1]. Advantages of cell lines include the relative ease of pharmacologic and genetic manipulation, the variety of available functional assays, and, for some studies, the purity of the cancerous epithelial population (and absence of stromal cell contamination). However, while some investigators choose particular cell lines based on the known ER or HER2 status, many others rely on standard "workhorses" like MCF7 without regard to the particular tumor subtypes being modeled. The recent recognition of microarray molecular subtypes points to the need for additional consideration in cell line selection.

The goal of our study was to profile gene expression and CNAs genome-wide in a collection of 52 publicly-available and commonly-used breast cancer cell lines, in order to assess the relation of these cell lines to the recognized molecular subtypes of breast cancer, and to discover new candidate breast cancer genes and pathways.

Materials and Methods {#s2}
=====================

Breast Cancer Cell Lines {#s2a}
------------------------

184A1, BT20, BT474, BT483, BT549, Hs578T, hTERT-HME1, MCF7, MCF10A, MDA-MB134, MDA-MB157, MDA-MB175, MDA-MB231, MDA-MB361, MDA-MB436, MDA-MB453, MDA-MB468, SKBR3, T47D, UACC812, UACC893, ZR75-1 and ZR75-30 were obtained from ATCC (Manassas, VA, USA). EFM19 and EFM192A were obtained from DSMZ (Braunschweig, Germany). HCC38, HCC70, HCC202, HCC712, HCC1007, HCC1143, HCC1395, HCC1419, HCC1428, HCC1500, HCC1569, HCC1599, HCC1806, HCC1937, HCC1954, HCC2157, HCC2185, HCC2218, HCC2688 and HCC3153 were obtained from the cell repository of the Hamon Center for Therapeutic Oncology Research, UT Southwestern Medical Center (many are now available from ATCC). CAL51 was a kind gift from J. Gioanni from the Centre Antoine-Lacassagne, Nice, France. SUM44PE, SUM52PE, SUM102PT, SUM149PT and SUM190PT were kind gifts from Dr. Stephen P. Ethier (now available from Asterand, Detroit, MI). MCF10A was grown in MEGM media (Cambrex, East Rutherford, NJ). SUM52PE and SUM149PT were grown in Ham\'s F12 media with 5% FBS, supplemented with 5 µg/ml insulin and 1 µg/ml hydrocortisone. SUM44PE, SUM102PT and SUM190PT were grown in Ham\'s F12 with 0.1% BSA, supplemented with 5 µg/ml insulin, 1 µg/ml of hydrocortisone, 5 mM ethanolamine, 10 mM HEPES, 5 µg/ml transferrin, 10 nM of Triiodo Thyronin (T3) and 50 nM sodium selenite (10 ng/ml EGF was also included for SUM102PT). All other cell lines were grown in RPMI-1640 with 10% FBS and 1% Pen/Strep. Clinicopathological characteristics of cell lines are summarized in [Table 1](#pone-0006146-t001){ref-type="table"}. A subset of cell lines (focused on the HCC series) was subjected to a more detailed molecular pathological characterization of *ESR1*, *PGR*, *ERBB2*, *EGFR* and *BRCA1*, as summarized in [Table 2](#pone-0006146-t002){ref-type="table"}.

10.1371/journal.pone.0006146.t001

###### Clinicopathological features of breast cancer cell lines.

![](pone.0006146.t001){#pone-0006146-t001-1}

  Cell line     Subtype[\#](#nt102){ref-type="table-fn"}   ER[\*](#nt103){ref-type="table-fn"}   PR[\*](#nt103){ref-type="table-fn"}   ERBB2/HER2[\*](#nt103){ref-type="table-fn"}   Source[€](#nt104){ref-type="table-fn"}   Tumor type[€](#nt104){ref-type="table-fn"}
  ------------ ------------------------------------------ ------------------------------------- ------------------------------------- --------------------------------------------- ---------------------------------------- --------------------------------------------
  184A1                            B                                        −                                    NA                                         −                                          RM                                         NA
  BT20                             A                                        −                                     −                                         −                                          PT                                         AC
  BT474                            L                                       \+                                    \+                                        \+                                          PT                                        IDC
  BT483                            L                                       \+                                    \+                                         −                                          PT                                        IDC
  BT549                            B                                        −                                     −                                         −                                          PT                                        IDC
  CAL51                            B                                        −                                    NA                                         −                                          PE                                         AC
  EFM19                            L                                       \+                                    \+                                         −                                          PE                                        IDC
  EFM192A                          L                                       \+                                    \+                                        \+                                          PE                                         AC
  HCC38                            B                                        −                                     −                                         −                                          PT                                         DC
  HCC70                            A                                        −                                     −                                         −                                          PT                                         DC
  HCC202                           L                                        −                                     −                                        \+                                          PT                                         DC
  HCC712                           L                                       \+                                     −                                         −                                          PT                                         DC
  HCC1007                          L                                       \+                                     −                                        \+                                          PT                                         DC
  HCC1143                          A                                        −                                     −                                         −                                          PT                                         DC
  HCC1187                          A                                        −                                     −                                         −                                          PT                                         DC
  HCC1395                          B                                        −                                     −                                         −                                          PT                                         DC
  HCC1419                          L                                        −                                     −                                        \+                                          PT                                         DC
  HCC1428                          L                                       \+                                    \+                                         −                                          PE                                       Met AC
  HCC1500                          L                                       \+                                    \+                                         −                                          PT                                         DC
  HCC1569                          A                                        −                                     −                                        \+                                          PT                                       Met C
  HCC1599                          A                                        −                                     −                                         −                                          PT                                         DC
  HCC1806                          NA                                       −                                     −                                         −                                          PT                                        Sq C
  HCC1937                          A                                        −                                     −                                         −                                          PT                                         DC
  HCC1954                          A                                        −                                     −                                        \+                                          PT                                         DC
  HCC2157                          A                                        −                                     −                                         −                                          PT                                         NA
  HCC2185                          L                                        −                                     −                                         −                                          PE                                       Met LC
  HCC2218                          L                                        −                                     −                                        \+                                          PT                                         DC
  HCC2688                          L                                        −                                    NA                                         −                                          PT                                         DC
  HCC3153                          A                                        −                                     −                                         −                                          PT                                         DC
  HS578T                           B                                        −                                     −                                         −                                          PT                                       C Sar
  hTERT-HME1                       B                                        −                                    NA                                         −                                          RM                                         NA
  MCF7                             L                                       \+                                    \+                                         −                                          PE                                       Met AC
  MCF10A                           B                                        −                                     −                                         −                                          RM                                         F
  MDA134                           L                                       \+                                     −                                         −                                          PE                                        IDC
  MDA157                           B                                        −                                     −                                         −                                          PE                                       Med C
  MDA175                           L                                       \+                                     −                                         −                                          PE                                        IDC
  MDA231                           B                                        −                                     −                                         −                                          PE                                       Met AC
  MDA361                           L                                       \+                                    \+                                        \+                                          BR                                       Met AC
  MDA436                           B                                        −                                     −                                         −                                          PE                                         AC
  MDA453                           L                                        −                                     −                        \+[¶](#nt105){ref-type="table-fn"}                          PE                                       Met C
  MDA468                           A                                        −                                     −                                         −                                          PE                                       Met AC
  SKBR3                            L                                        −                                     −                                        \+                                          PE                                         AC
  SUM44                            NA                                      \+                                    \+                                        \+                                          PE                                        ILC
  SUM52                            L                                       \+                                     −                                        \+                                          PE                                       Met C
  SUM102                           B                                        −                                     −                                         −                                          PE                                   IDC, apocrine
  SUM149                           B                                        −                                     −                                         −                                          PE                                        Inf
  SUM190                           L                                        −                                     −                                        \+                                          PT                                        Inf
  T47D                             L                                       \+                                    \+                                         −                                          PE                                        IDC
  UACC812                          L                                       \+                                     −                                        \+                                          PT                                        IDC
  UACC893                          L                                        −                                     −                                        \+                                          PT                                        IDC
  ZR75-1                           L                                       \+                                     −                                         −                                          AF                                        IDC
  ZR75-30                          L                                       \+                                     −                                        \+                                          AF                                        IDC

Abbreviations: A = Basal A subtype; AC = adenocarcinoma; AF = ascites fluid; B = Basal B subtype; BR = brain; C Sar = carcinoma sarcoma; DC = ductal carcinoma; F = fibrocystic disease; IDC = invasive ductal carcinoma; Inf = inflammatory carcinoma; ILC = invasive lobular carcinoma; L = Luminal subtype; Med C = medullary carcinoma, Met AC = metastatic adenocarcinoma; Met C = metastatic carcinoma, Met LC = metastatic lobular carcinoma; NA = not available; PE = pleural effusion; PT = primary tumor; RM = reduction mammoplasty; Sq C = Squamous Carcinoma.

Determined from this study.

Determined from the ATCC (<http://www.atcc.org>) and DSMZ (<http://www.dsmz.de>) websites, and references therein, or from this study.

Determined from the ATCC and DSMZ websites, and references therein.

*ERBB2* amplified but not highly expressed.

10.1371/journal.pone.0006146.t002

###### Molecular pathological analysis of breast cancer cell line subset.

![](pone.0006146.t002){#pone-0006146-t002-2}

  Cell line    Phenotype      BRCA1      Q-PCR[\#](#nt106){ref-type="table-fn"} ERBB2   Q-RT-PCR[\*](#nt107){ref-type="table-fn"}    IHC    Western                                                          
  ----------- ------------ ------------ ---------------------------------------------- ------------------------------------------- ------- --------- ------- ------- ------- ------- ------- ------- ------- -------
  HCC38        Triple neg                                    1.18                                           −                         −        −        −     **−**   **−**   **−**   **−**   **−**   **−**   **−**
  HCC70        Triple neg                                    0.37                                           −                         −        −       \+     **−**   **−**   **−**   **−**   **−**   **−**   **+**
  HCC202       ERBB2 amp                                  **28.88**                                       **−**                     **−**    **+**    **+**   **−**   **−**   **+**   **−**   **−**   **+**   **+**
  HCC712        Hormone+                                     0.95                                         **+**                     **−**    **−**    **−**   **+**   **+**           **+**   **−**   **−**   **−**
  HCC1143      Triple neg                                    1.08                                         **−**                     **−**    **−**    **+**   **−**   **−**   **−**   **−**   **−**   **−**   **+**
  HCC1187      Triple neg                                    0.42                                         **−**                     **−**    **−**    **−**           **−**   **−**   **−**   **−**   **−**   **+**
  HCC1395      Triple neg                                    0.36                                         **−**                     **−**    **−**    **−**   **−**   **−**   **−**   **−**   **−**   **−**   **−**
  HCC1419      ERBB2 amp                                   **8.39**                                       **−**                     **−**    **+**    **−**   **−**           **+**   **−**   **−**   **+**   **−**
  HCC1428       Hormone+                                     0.20                                         **+**                     **+**    **−**    **−**   **+**   **+**   **−**   **+**   **+**   **−**   **−**
  HCC1500       Hormone+                                     0.38                                         **+**                     **+**    **−**    **−**   **+**   **+**   **−**   **+**   **−**   **−**   **−**
  HCC1569      ERBB2 amp                                  **33.75**                                       **−**                     **−**    **+**    **+**   **−**   **−**   **+**   **−**   **−**   **+**   **+**
  HCC1806      Triple neg                                    0.08                                         **−**                     **−**    **−**    **+**   **−**   **−**   **−**   **−**   **−**   **−**   **+**
  HCC1937      Triple neg   INS C 5382                       0.33                                         **−**                     **−**    **−**    **+**   **−**   **−**   **−**   **−**   **−**   **−**   **+**
  HCC1954      ERBB2 amp                                  **45.01**                                       **−**                     **−**    **+**    **+**   **−**   **−**   **+**   **−**   **−**   **+**   **+**
  HCC2185      Triple neg                                    0.63                                         **−**                     **−**    **−**    **+**   **−**   **−**           **−**   **−**   **−**   **+**
  HCC3153      Triple neg   943 ins 10                       0.64                                         **−**                     **−**    **−**    **+**   **−**   **−**   **−**   **−**   **−**   **−**   **+**
  MCF7          Hormone+                                     0.56                                         **+**                     **−**    **−**    **−**                           **+**   **−**   **−**   **−**
  BT483         Hormone+                                     0.19                                         **+**                     **+**    **−**    **−**                           **+**   **+**   **−**   **−**
  BT549        Triple neg                                    0.63                                         **−**                     **−**    **−**    **+**                           **−**   **−**   **−**   **+**
  MDA157       Triple neg                                    0.76                                         **−**                     **−**    **−**    **+**                           **−**   **−**   **−**   **−**
  MDA231       Triple neg                                    0.90                                         **−**                     **−**    **−**    **+**                           **−**   **−**   **−**   **+**
  MDA453       Triple neg                                    3.88                                         **−**                     **−**    **+**    **−**                           **−**   **−**   **−**   **−**
  MDA134        Hormone+                                     0.76                                         **+**                     **−**    **−**    **−**                           **+**   **−**   **−**   **−**
  MDA175       Triple neg                                    0.57                                         **−**                     **−**    **−**    **−**                           **−**   **−**   **−**   **−**
  HMEC1585      Control                                      0.54                                         **−**                     **−**    **−**    **+**                           **−**   **−**   **−**   **+**
  CALU3         Control                                   **12.59**                                       **−**                     **−**    **+**    **+**                           **−**   **−**   **+**   **+**
  NC11          Control                                      1.75                                         **−**                     **−**    **−**    **−**                           **−**   **−**   **−**   **−**
  DNA20         Control                                      2.00                                                                                                                                            

Gene copy number determined using DNA20 (from normal lymphocytes) as a diploid control; bold values indicate amplification.

mRNA expression quantified in comparison to the immortalized breast line HMEC1585; Calu3 was used a positive control for *ERBB2*, and MCF7 for *ESR1*.

RNA and DNA isolation {#s2b}
---------------------

Cells were grown to 70--80% confluence, then harvested for total RNA and genomic DNA. For HCC lines, RNA was prepared using the Qiagen RNeasy Midi Kit (Qiagen, Valencia, CA) and DNA by phenol/chloroform extraction. For all other lines, RNA was isolated using Trizol (Invitrogen, Carlsbad, CA) according to the manufacturer\'s protocol, and DNA using the Blood Cell Maxi Kit (Qiagen).

*ERBB2* copy number assessment by quantitative PCR {#s2c}
--------------------------------------------------

*ERBB2* copy number was quantified by real-time quantitative PCR (Q-OCR), using the Chromo4 PCR System (Bio-Rad Laboratories, Hercules, CA). *GAST*, located at 17q21 (on the same chromosomal arm as *ERBB2*) was used as a reference control. PCR primer sequences for *ERBB2* and *GAST* are as follows (forward and reverse, respectively): *ERBB2*( 5′-TTGGGAGCCTGGCATTTCT-3′ and 5′-AGGTCATCGTGCCCACTCTT-3′); *GAST* (5′-GTAGGCATCCTTCCCCCATT-3′ and 5′-AGCCATGGTCCCTGCTTCTT-3′), with PCR product lengths of 59 and 70 base pairs, respectively. Primers were chosen by TaqMan Primer Express™ 1.5 (Applied Biosystem, Foster City, CA) and purchased from Invitrogen. PCR reactions were carried out in a final volume of 20 µl containing 20 ng genomic DNA, 300 nM each primer (for both *ERBB2* and *GAST*, in independent reactions) and 1× Power SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA). PCR conditions were as follows: one cycle at 95°C for 10 minutes, followed by 40 cycles each at 95°C for 15 seconds and 60°C for 1 minute. Samples were analyzed in triplicate. Each amplification reaction was checked for the absence of nonspecific PCR products by melting curve analysis. *ERBB2* copy number calculation was carried out using the comparative Ct method [@pone.0006146-Livak1] after validating that the efficiencies of PCR reactions of both *ERBB2* and *GAST* were equal. Human Genomic DNA (DNA20) (EMD Biosciences, Darmstadt, Germany), a mixture of pooled human whole blood from 6--8 individual male and female donors, was run in every assay as a calibrator sample. *ERBB2* gene copy number in normal human genomic DNA was set as 2 and copy number more than 4 in cell lines was considered to be increased.

mRNA levels of *ESR1, PGR, ERBB2* and *EGFR* {#s2d}
--------------------------------------------

Transcript levels of *ESR1, PGR, ERBB2* and *EGFR* were analyzed as a part of RT2 Profiler Custom PCR Array (SuperArray Bioscience, Frederick, MD). After making cDNA from 1.0 µg total RNA using RT2 PCR Array First Strand Kit (SuperArray Bioscience), quantitative PCR was performed with the Chromo4 PCR System (Bio-Rad Laboratories) using RT2 Real-Time SYBR Green PCR Master Mix (SuperArray Bioscience) according to the manufacturer\'s protocol. We chose two different housekeeping genes, β-actin (*ACTB*) and glyceraldehyde-3-phosphate dehydrogenase (*GAPDH*) as internal controls, using the average of their Ct values. Primers were chosen by Taqman Primer Express™ 1.5 and purchased from Invitrogen, as follows: (forward and reverse, respectively): *ESR1* (5′-ATCTCGGTTCCGCATGATGAATCTGC-3′ and 5′-TGCTGGACAGAAATGTGTACACTCCAGA-3′); *PGR* (5′-CCTGTGGGAGCTGTAAGGTCTT-3′ and 5′-GCAGTCATTTCTTCCAGCACATA-3′), *ERBB2* (5′-TGACCTGCTGGAAAAGGGGGAGCG-3′ and 5′-TCCCTGGCCATGCGGGAGAATTCAG-3′); *EGFR* (5′-ATAGTCGCCCAAAGTTCCGTGAGT-3′ and 5′-ACCACGTCGTCCATGTCTTCTTCA-3′); *ACTB* (5′ GGCTGTGCTGTGGAAGCTAAG-3′ and 5′-ATGATGGAGTTGAAGGTAGTTTCGT-3′) [@pone.0006146-Potemski1]. We also analyzed the values of NC11 (normal lymphocyte) cell line for *ESR1, PGR, ERBB2* and *EGFR* mRNA expression, and the tumor cell values were reported relative to NC11. For data analysis, the comparative Ct method [@pone.0006146-Livak1] was used.

Western blot analysis and immunohistochemistry (IHC) {#s2e}
----------------------------------------------------

Preparation of total cell lysates and Western blotting were done as described previously [@pone.0006146-Sato1]. Primary antibodies used were mouse monoclonal anti-ER-α (Cell Signaling, Beverly, MA), mouse monoclonal PR (6A1) (Cell Signaling), mouse monoclonal anti-HER2 (Cell Signaling), rabbit monoclonal anti-EGFR (Cell Signaling) and mouse monoclonal anti-actin (Sigma-Aldrich). Actin levels were used as a control for protein loading. Peroxidase-labeled anti-mouse or anti-rabbit antibodies (Amersham Pharmacia, Piscataway, NJ) were used as secondary antibody. IHC on breast cancer cell lines was described previously [@pone.0006146-Wistuba1].

*BRCA1* mutation analysis {#s2f}
-------------------------

DNA sequence analysis was performed on the entire *BRCA1* gene in available lymphocyte DNA matched to breast cancer cell lines. In the lymphocyte DNA matching HCC3153, a heterozygous duplication of 10 base pairs was detected at position 943 in exon 11 of *BRCA1* (943ins10). The region of BRCA1 exon 11 containing the 943ins10 mutation was amplified from genomic DNA in the tumor cell line (HCC3153) using standard PCR conditions. Sequence analysis revealed only the mutant sequence. Absence of the normal allele was also confirmed by single strand conformation analysis as well as gel electrophoresis of the amplified fragment on 5% acrylamide denaturing gels.

Gene expression profiling {#s2g}
-------------------------

Gene expression profiling was performed on Human Exonic Evidence Based oligonucleotide (HEEBO) arrays obtained from the Stanford Functional Genomics Facility and containing 36,192 oligonucleotides representing 18,141 mapped human genes. 40 µg of sample RNA and 40 µg of "universal" reference RNA (derived from 11 different established human cell lines) were differentially labeled with Cy5 and Cy3, respectively, using an amino-allyl coupling protocol, then cohybridized onto the microarray in a high volume mixing hybridization at 65°C for 40 hrs. Details of the array processing and sample labeling/hybridization methods have been described [@pone.0006146-Bergamaschi2]. Following hybridization, arrays were washed and scanned using a GenePix 4000B Axon scanner (Axon Instruments, Union City, CA). Fluorescence ratios were extracted using Spot Reader software (Niles Scientific, Portola Valley, CA) and uploaded to the Stanford Microarray Database [@pone.0006146-Demeter1] for storage, retrieval, and analysis. For two lines, HCC1806 and SUM44PE, expression profiling array hybridizations did not meet quality-control inspection and were excluded from analysis. The complete microarray expression data are available at the Stanford Microarray Database (SMD) (<http://smd.stanford.edu>) and at the Gene Expression Omnibus (GEO) (accession GSE15376); all microarray data reported in the manuscript are described in accordance with MIAME guidelines.

Gene expression profiling analysis {#s2h}
----------------------------------

Background-subtracted fluorescence log~2~ ratios were globally normalized for each array, and then mean-centered for each gene (i.e. reporting relative to the average log ratio across all samples). Unless otherwise specified, we included for subsequent analysis only well-measured genes defined as those with fluorescence intensities in the Cy5 or Cy3 channel at least 1.5-fold above background in at least 60% of samples. For unsupervised hierarchical clustering, we included only the 8,750 well-measured genes whose expression varied at least 3-fold from the mean in at least 5 samples ([Table S1](#pone.0006146.s001){ref-type="supplementary-material"}). Hierarchical clustering was performed and displayed using Cluster and TreeView software (<http://rana.lbl.gov/EisenSoftware.htm>). Enrichment for functionally related genes was tested across a collection of 1,687 curated gene sets (C2) using Gene Set Enrichment analysis (GSEA; Release 2.0) [@pone.0006146-Subramanian1]. Cell lines were classified according to breast tumor subtype (luminal-A, luminal-B, ERBB2, basal-like and normal-like) using the nearest centroid method applied to the set of "intrinsic genes" (i.e. genes with small within-specimen compared to between-specimen expression variance), as done previously [@pone.0006146-Sorlie2], here using Euclidean distance. To classify breast tumors (from the Sorlie *et al*. dataset [@pone.0006146-Sorlie1]) according to cell line subtype (luminal, basal A, or basal B), we first built a classifier by combining the top 100 genes positively and negatively correlating with each of the three "one *vs*. others" cell line subtype distinctions, using Significance Analysis of Microarrays (SAM) [@pone.0006146-Tusher1]. The cell line subtype classifier, comprising 484 genes, was then applied to classify primary tumors using the nearest centroid method (with Euclidean distance). We also classified each cell line as being associated with a good or bad prognosis signature (70-gene prognostic signature [@pone.0006146-vantVeer1]), the presence or absence of a wound healing signature (512-gene wound signature [@pone.0006146-Chang1]), and the presence or absence of an hypoxia signature (123-gene hypoxia signature [@pone.0006146-Chi1]). For each signature, we calculated the gene expression centroid of the two groups of breast tumors (as determined in the original publications), and then correlated each centroid with cell line expression of the respective signature genes. Membership was assigned to the group with the highest correlation (Pearson correlation).

Array-based comparative genomic hybridization (aCGH) {#s2i}
----------------------------------------------------

Arrays for CGH were obtained from the Stanford Functional Genomics Facility. aCGH was performed using cDNA arrays containing 39,632 cDNAs, representing 22,279 mapped human genes (18,049 UniGene clusters [@pone.0006146-Schuler1], together with 4,230 additional mapped ESTs not assigned to UniGene IDs), according to previously published protocols [@pone.0006146-Pollack1], [@pone.0006146-Pollack2]. Briefly, 4 µg of genomic DNA from cell lines was random-primer labeled with Cy5 and co-hybridized onto a microarray along with 4 µg of Cy3 labeled normal leukocyte female reference DNA. Following overnight hybridization, the arrays were washed and scanned as above. The complete aCGH data are available at SMD and at GEO (accession GSE15376).

aCGH analysis {#s2j}
-------------

Background-subtracted log~2~ fluorescence ratios were normalized for each array by mean centering. Well-measured genes used for subsequent analysis were those with fluorescence intensities in the Cy3 reference channel at least 1.4 fold above background. Map positions for arrayed cDNA clones were assigned using the NCBI genome assembly, accessed through the UCSC genome browser database (NCBI Build 36.1). For genes represented by multiple arrayed cDNAs, the average log~2~ ratio was used. The complete processed aCGH dataset is available as [Table S2](#pone.0006146.s002){ref-type="supplementary-material"}. DNA gains and losses were identified using the cghFLasso (R package for Fused Lasso) method [@pone.0006146-Tibshirani1], which controls the false discovery rate (FDR) by using normal-normal hybridization arrays to approximate the null distribution of the test statistics (see [@pone.0006146-Tibshirani1] for more details). A FDR\<1% was used to call gains and losses. The fraction of the genome altered was determined by calculating the fraction of genes with fluorescence ratios ≥3 (for amplifications) or with significant non-zero fused lasso calls (for gains and losses). Some analyses (where indicated) were carried out on cytobands (boundaries defined by NCBI Build 36.1) rather than individual genes. For each cell line, cytobands exhibiting CNA were defined as those with at least two genes called by cghFLasso, and the magnitude of the CNA defined as the average log~2~ ratio of genes within the cytoband. We defined high-level DNA amplifications and multi-copy deletions as continuous regions identified by cghFLasso with at least 50% of genes having fluorescence ratios ≥3 or ≤0.25 respectively. These sites were also checked against known copy number variants (CNVs) reported in the Database of Genomic Variants (<http://projects.tcag.ca/variation>). Significant associations between cytobands and gene-expression subtypes were identified using SAM with a FDR\<5%.

Integrating genomic and transcriptional profiles {#s2k}
------------------------------------------------

To integrate DNA copy number data (generated using cDNA microarrays) and gene-expression data (HEEBO oligonucleotide arrays), each gene expression measurement was first assigned a DNA copy number from either a probe interrogating the same named gene, or the average copy number of the nearest 5′ and 3′ probes (NCBI Build 36.1). Identification of genes with correlated copy number and expression was carried out using the DR-Correlate application of DR-Integrator (K. Salari, manuscript in preparation). Briefly, for each gene a modified Student\'s *t*-test was performed comparing gene expression levels in cell lines from the lowest and the highest deciles of all cell lines\' copy number for the same gene; random permutations of sample labels were used to estimate a FDR.

Results {#s3}
=======

Transcriptional profiling identifies three breast cancer cell line subtypes {#s3a}
---------------------------------------------------------------------------

To catalog molecular variation in a collection of 52 widely-used breast cancer cell lines, we first profiled gene expression using whole genome oligonucleotide microarrays. Unsupervised hierarchical clustering of the 8,750 most variably expressed genes stratified cell lines into two main groups (see dendrogram, [Fig. 1B](#pone-0006146-g001){ref-type="fig"}). One group, designated "luminal" (blue dendrogram branches), contained all the ER-positive cell lines ([Fig. 2A](#pone-0006146-g002){ref-type="fig"}), and was characterized by the expression of ERα-regulated genes (e.g. *MYB*, *RET*, *EGR3*, *TFF1*; [Fig. 1H](#pone-0006146-g001){ref-type="fig"}, and not shown) [@pone.0006146-Gudas1]--[@pone.0006146-Jeltsch1], as well as genes associated with luminal epithelial differentiation (e.g. *GATA3* and *FOXA1*, [Fig. 1I](#pone-0006146-g001){ref-type="fig"}) [@pone.0006146-KourosMehr1].

![Clustering of expression profiles defines breast cancer cell line subtypes.\
(A) Thumbnail "heatmap" of two-way hierarchical clustering of 50 breast cancer cell lines (columns) and 8,750 variably expressed genes (rows) (data available as [Table S1](#pone.0006146.s001){ref-type="supplementary-material"}). Gene expression ratios are depicted by log~2~ pseudocolor scale shown; gray represents poorly measured data. (B) Enlarged view of the sample dendrogram. Clustering stratifies cell lines into two main groups, luminal (blue dendrogram branches) and basal, the latter further subdivided into two subgroups, basal A (red) and basal B (orange). (C--I) Selected gene expression patterns extracted from the cluster; corresponding locations in the thumbnail are indicated by the vertical colored bars. (C) Basal-B; (D) Basal cytokeratins; (E) Basal; (F) Basal-A; (G) Luminal cytokeratins; (H) ER-associated; (I) Luminal differentiation.](pone.0006146.g001){#pone-0006146-g001}

![Subtype-specific expression and molecular characteristics.\
(A) Clinical, pathological and molecular characteristics of cell line expression subtypes. Black boxes indicate metastasis derivation, ER-positivity, *TP53* mutation, *ERBB2*/HER2 positivity, *PTEN* mutation, *PIK3CA* mutation. Mutation data compiled from the Sanger (<http://www.sanger.ac.uk>) and IARC (<http://www-p53.iarc.fr>) websites, and from refs. [@pone.0006146-Hollestelle1], [@pone.0006146-StemkeHale1]. White cross-hatched boxes indicate missing data. (B) Classification of cell lines by nearest resemblance to tumor gene-expression subtype: luminal A (dark blue), luminal B (light blue), ERBB2-associated (purple), basal-like (red) or normal-like (green); and by positivity (black boxes) for 70-gene, wound and hypoxia signature. (C) Expression levels of selected stem/progenitor cell relevant markers; log~2~ ratios are depicted by pseudocolor scale shown (gray represents poorly measured data). (D) Relation of tumor subtypes to cell line subtypes. Subtype of 86 tumors [@pone.0006146-Sorlie1] is shown color-coded as above. Resemblance to each cell line subtype is depicted by Euclidian distance, indicated by blue intensity (representing shorter distances); best match is bracketed in black.](pone.0006146.g002){#pone-0006146-g002}

The other group, designated "basal", contained only ER-negative cell lines ([Fig. 2A](#pone-0006146-g002){ref-type="fig"}) and was characterized by the expression of basal epithelial gene markers including MSN, ETS1, CAV1 and EGFR ([Fig. 1E](#pone-0006146-g001){ref-type="fig"}, and not shown) [@pone.0006146-Jones1]--[@pone.0006146-CharafeJauffret2]. Basal cell lines were further stratified into two subgroups, designated A and B (in line with Neve *et al*. [@pone.0006146-Neve1], discussed further below). The basal-A subtype (red dendrogram branches) contained many of the "HCC" lines established at UT Southwestern, including two known *BRCA1* mutant lines (HCC1937, HCC3153) ([@pone.0006146-Tomlinson1], and this study). Basal-A lines were characterized by expression of PROM1 (aka CD133), a marker of various cancer stem cells [@pone.0006146-Neuzil1], as well as other genes like *GABRP* and *VTCN1* ([Fig. 1F](#pone-0006146-g001){ref-type="fig"} and [2C](#pone-0006146-g002){ref-type="fig"}). Some of the basal-A lines also shared expression of luminal epithelial markers like KRT8 and KRT18 ([Fig. 1G](#pone-0006146-g001){ref-type="fig"}).

The basal-B subtype (orange dendrogram branches) included non-tumorigenic lines (MCF10A, hTERT-HME1, 184A1) as well as several highly invasive lines exhibiting features of epithelial-mesenchymal transition (EMT) (MDA-MB231, MDA-MB436, MDA-MB157, Hs578t) [@pone.0006146-Bae1]. Basal-B lines were characterized by markers associated with aggressive tumor features, including PLAT (plasminogen activator) [@pone.0006146-HolstHansen1] and TGFB1 [@pone.0006146-Dumont1] ([Fig. 1C](#pone-0006146-g001){ref-type="fig"}), as well as marker phenotypes associated with normal breast and breast cancer progenitor/stem cells (MUC^−^/CALLA^+^; CD44^+^/CD24^−/low^; and ITGB3(CD61)^+^) ([Fig. 2C](#pone-0006146-g002){ref-type="fig"}) [@pone.0006146-Stingl1]--[@pone.0006146-Vaillant1]. In contrast to other basal lines, the subset of mesenchymal-like basal-B lines lacked expression of basal cytokeratin markers KRT5 and KRT17 ([Fig. 1D](#pone-0006146-g001){ref-type="fig"}, and not shown).

Subtype-specific differences in gene expression could also be identified by pathway analysis, using Gene Set Enrichment Analysis (GSEA) [@pone.0006146-Subramanian1]. Included among the top signature associations ([Table 3](#pone-0006146-t003){ref-type="table"}), the luminal cell line subtype was characterized by enriched expression of ER and good prognosis signatures, basal-A by ETS pathway and BRCA1 signatures, and basal-B by EMT and epidermal growth factor (EGF) signatures.

10.1371/journal.pone.0006146.t003

###### GSEA of breast cancer cell line subtypes.

![](pone.0006146.t003){#pone-0006146-t003-3}

  Subtype          Gene Set                             Description                                Source              FDR[\*](#nt108){ref-type="table-fn"}
  --------- ----------------------- --------------------------------------------------- ----------------------------- --------------------------------------
  Luminal         BRCA_ER_POS              Correlated with ER+ in breast cancer           [@pone.0006146-vantVeer1]                   0.017
              BRCA_PROGNOSIS_POS      Correlated with good prognosis in breast cancer                                                 0.094
  Basal-A         ETSPATHWAY                 ETS transcription factor pathway                     BioCarta                            0.063
                BRCA_BRCA1_POS       Correlated with BRCA1 (germline) in breast cancer    [@pone.0006146-vantVeer1]                   0.063
                  IFN_ALL_UP            Upregulated with interferon-α,β,γ treatment         [@pone.0006146-Der1]                      0.071
                IFNALPHA_HCC_UP           Upregulated with interferon-α treatment         [@pone.0006146-Radaeva1]                    0.076
                   GLYCOGEN                         Glycogen processing                        Broad Institute                        0.078
  Basal-B      JECHLINGER_EMT_UP                    Upregulated in EMT                   [@pone.0006146-Jechlinger1]                  0.040
                 EGF_HDMEC_UP                 Upregulated with EGF treatment               [@pone.0006146-Zhang2]                     0.042
             DORSEY_DOXYCYCLINE_UP           Upregulated with GAB2 expression              [@pone.0006146-Dorsey1]                    0.047
                   HTERT_DN              Downregulated with hTERT-immortalization         [@pone.0006146-Lindvall1]                   0.048
                HINATA_NFKB_UP                     Upregulated by NF-κB                    [@pone.0006146-Hinata1]                    0.049

Only top five significant gene sets shown.

In regard to molecular markers and gene mutations ([Fig. 2A](#pone-0006146-g002){ref-type="fig"}), the luminal subtype included all the ER-positive cancer lines (*P*\<0.001, 2-tailed Fisher\'s exact test), and all but two of the ERBB2-positive lines (*P* = 0.002), half of which were also ER-positive. *PTEN* inactivating mutations and *PIK3CA* activating mutations, functioning on the same pathway, were mutually exclusive in all but one sample. Interestingly, *PTEN* mutations were more common in the combined basal-like cell lines (*P* = 0.020), while *PIK3CA* mutations were more frequent in luminal lines (*P* = 0.022). *TP53* mutations occurred more often in basal-like lines (*P* = 0.038).

Relationship of breast cancer cell line and tumor subtypes {#s3b}
----------------------------------------------------------

To determine the relation between breast cancer cell line subtypes (luminal, basal-A, basal-B) and breast tumor subtypes (luminal-A, luminal-B, ERBB2, basal-like, and normal-like), we first classified cell lines according to tumor subtype using a nearest centroid approach applied to the set of "intrinsic genes" used originally to define the tumor subtypes [@pone.0006146-Perou1], [@pone.0006146-Sorlie1] (see [Methods](#s2){ref-type="sec"}) ([Fig. 2B](#pone-0006146-g002){ref-type="fig"}). By expression patterns, most of the luminal lines most closely resembled either luminal-A or luminal-B tumors. Most basal-A lines resembled basal-like tumors, and most basal-B lines resembled either basal-like or ERBB2 tumors (despite that none were ERBB2-positive).

We also carried out the reverse analysis, building a cell line subtype classifier to classify 86 breast tumors (from the original Stanford/Norway study defining the five tumor subtypes [@pone.0006146-Sorlie1]) according to cell line subtype (see [Methods](#s2){ref-type="sec"}) ([Fig. 2D](#pone-0006146-g002){ref-type="fig"}). Notably, all basal-like tumors most resembled basal-A cell lines. Luminal-A and -B tumors most resembled luminal cell lines, while ERBB2 subgroup tumors most resembled either luminal or basal-A cell lines. A similar analysis of breast tumors arising in carriers of *BRCA1* mutation, analyzed from a different dataset (The Netherlands Cancer Institute) [@pone.0006146-vantVeer1], revealed highest resemblance in 17 of 18 cases to basal-A lines (not shown), while two *BRCA2* mutation associated cases most resembled luminal cell lines.

In addition to the above cluster-derived luminal/basal tumor subtypes, alternative breast tumor subtype classifiers have been proposed, including a 70-gene prognostic signature supervised on the metastatic/non-metastatic distinction [@pone.0006146-vantVeer1], a "wound" signature trained on the serum response of cultured fibroblasts [@pone.0006146-Chang1], and a hypoxia signature derived from the hypoxic response of cultured mammary and renal tubular epithelial cells [@pone.0006146-Chi1]. Each of the three signatures predicts unfavorable clinical outcome. Interestingly, the basal-like lines (considered together) were those predominantly expressing the 70-gene (*P* = 0.001, Fisher\'s exact test) wound (*P* = 0.004), and hypoxia (*P*\<0.001) signatures ([Fig. 2B](#pone-0006146-g002){ref-type="fig"}).

Genomic profiles of breast cancer cell lines {#s3c}
--------------------------------------------

To survey DNA copy number alterations in the panel of 52 breast cancer cell lines, we carried out CGH on cDNA microarrays with validated performance characteristics [@pone.0006146-Pollack1] and covering 22,000 genes with an average mapping resolution (inter-probe distance) of \<70 Kb. Across the sample set, the most frequent CNAs (called by cghFLasso--see [Methods](#s2){ref-type="sec"}) were gains on 1q, 3q, 5p, 7p, 8q, 11q, 17q, and 20q, and losses on 3p, 4, 8p, 9p, 11q, 13q, 18p, and Xq.

Overall, the spectrum of cytoband gains and losses was similar in the cell lines compared to primary tumors ([Fig. 3A](#pone-0006146-g003){ref-type="fig"}), though the frequency of those CNAs was generally higher with the cell lines. Cell line subtype-specific CNAs could be identified by SAM analysis ([Fig. 3B](#pone-0006146-g003){ref-type="fig"}). Luminal cell lines were characterized by more frequent gains on 1q, 8q, 11q, 12q, 14q, 17q and 20q, and losses on 8p, 9p, 11q, 13q, and 18p. Of these, gains on 1q, 8q, and 20q, and losses on 1p, 8p and 13q (asterisked in [Fig. 3B](#pone-0006146-g003){ref-type="fig"}) also characterize luminal-B breast tumors, while 17q gain characterizes ERBB2-associated tumors [@pone.0006146-Bergamaschi1], [@pone.0006146-Chin1]. Notably, simple patterns characteristic of luminal-A tumors (1q+, 16p+, 16q−) were not well-represented among the luminal cell lines. Basal-A and basal-B cell lines also exhibited characteristic gains/losses ([Fig. 2B](#pone-0006146-g002){ref-type="fig"}), but none also selectively characteristic of basal-like tumors.

![Genomic profiles define spectra of CNAs in cell line subtypes.\
(A) Spectra of gains (red) and losses (green) across the genome, plotted as average log~2~ ratio, for 89 breast tumors [@pone.0006146-Bergamaschi1], above, compared to the set of 50 cell lines (profiled for both expression and CNAs), below. (B) Spectra of gains and losses for the cell line subtypes: luminal (above), basal A (middle) and basal B (below). Statistically significant subtype-specific CNAs, called by SAM (FDR\<5%), are marked by a black bar. The subset of those loci that also characterize the corresponding primary breast tumor subtype is marked by an asterisk.](pone.0006146.g003){#pone-0006146-g003}

Luminal cell lines displayed overall higher frequencies of high-level DNA amplification (i.e. fluorescence ratios ≥3, corresponding to at least 5-fold amplification [@pone.0006146-Pollack1]) ([Fig. 4A](#pone-0006146-g004){ref-type="fig"}), a characteristic shared with luminal-B tumors [@pone.0006146-Bergamaschi1]. Luminal and basal-A lines both exhibited overall higher frequencies of gain/loss (a characteristic feature of basal-like tumors [@pone.0006146-Bergamaschi1]), compared to basal-B lines ([Fig. 4B](#pone-0006146-g004){ref-type="fig"}).

![Cell line subtypes exhibit distinct genomic instabilities.\
Fraction of genome comprising (A) high-level DNA amplification; or (B) low-level gain/loss, stratified by cell line subtype (luminal, basal-A, basal-B). Box plots show 25^th^, 50^th^ and 75^th^ percentiles; *P*-values (Students *t*-test) for pairwise comparisons are shown.](pone.0006146.g004){#pone-0006146-g004}

Integrated analysis for cancer gene discovery {#s3d}
---------------------------------------------

The molecular profiles generated provide opportunities to identify breast cancer cell lines with an altered copy number and expression of known cancer genes, useful to model pathogenesis and therapy, and to discovery new breast cancer genes. For the latter, high-amplitude CNAs, i.e. high-level DNA amplifications and homozygous deletions, are particularly informative in pinpointing new cancer genes. Within the aCGH dataset we identified 80 loci of high-level amplification in 35 different cell lines, each spanning 49--49,014 Kb (median 1,115 Kb). We also identified 13 multi-copy (possibly homozygous) deletions (fluorescence ratios ≤0.25) in 8 cell lines spanning 132--7,825 Kb (median 1,477 Kb). The boundaries of amplicons/deletions did not correspond to known germline CNVs (reported in the Database of Genomic Variants), and, for the subset of recurrent alterations, finding distinct boundaries in different cell lines was more consistent with somatic alteration. Several regions of high-level amplification contained known oncogenes, like 8q24 (*MYC*), 11q13 (*CCND1*) and 17q12 (*ERBB2*). Other amplicons did not correspond to known oncogenes and presumably harbor novel breast cancer genes.

Gains and losses contribute to breast cancer by the increased and decreased expression of oncogenes and tumor suppressors, respectively. Using DR-Correlate (see [Methods](#s2){ref-type="sec"}), we identified 3,511 genes (∼18% of all well-measured genes) whose altered expression correlated significantly (FDR\<0.05) with altered gene copy number ([Table S3](#pone.0006146.s003){ref-type="supplementary-material"}). Of these, 487 resided within loci of high-amplitude CNA ([Table 4](#pone-0006146-t004){ref-type="table"}). This subset included known breast cancer genes, like *EGFR* (7p11), *FGFR1* (8p12), *ERBB2* (17q12), *PPM1D* (17q23) and ZNF217 (20q13). This subset is likely also enriched for novel breast cancer genes, and as such represents a rich source for cancer gene discovery. Notably, among the larger group of amplified/overexpressed genes are several with known functions relevant to oncogenesis, like cell proliferation (e.g. *EIF3H*, *HEY1*, *MELK*, *GAB2*, CDC6, *GRB2*) [@pone.0006146-Zhang1]--[@pone.0006146-BentiresAlj1], survival (e.g. *HIPK1*, *MCL1*, *MAPKAPK2*, *VCP*, *VDAC2*, *APIP*, *MAP3K3*) [@pone.0006146-Kondo1]--[@pone.0006146-Samanta1], migration/invasion (e.g. *MUC1*, *ADAM9*, *SH3PXD2A*, *CD44*, *PAK1*, *GIT1*, *PTPN1* ) [@pone.0006146-Schroeder1]--[@pone.0006146-Cheng2], ER-signaling (e.g. *BCAS2*, *MUC1*, *NCOA3*, *TFAP2C* ) [@pone.0006146-Qi1]--[@pone.0006146-Woodfield1], and maintenance of genome integrity (e.g. *NBN*, *RAD21*, *FANCG*, *BUB3*, *RAD9A*, *TAOK1*, *RAD51C*, *RAE1*) [@pone.0006146-Varon1]--[@pone.0006146-French1]. Also represented are several "druggable" classes [@pone.0006146-Hopkins1], like kinases (e.g. *HIPK1*, *MAPKAPK2*, *MELK*, *RPS6KB2*, *PAK1*, *TAOK1*, *PIP4K2B*, *RPS6KB1*, *TLK2*, *MAP3K3*), phosphatases (e.g. *PTPN1*), proteases (e.g. *ADAM9*), G protein-coupled receptors (e.g. *GPRC5C*) and ion channels (e.g. *VDAC2*).

10.1371/journal.pone.0006146.t004

###### High-amplitude amplifications and deletions.

![](pone.0006146.t004){#pone-0006146-t004-4}

  Cytoband             P-Border (nt)   Q-Border (nt)   Size (kB)                                    Cell Lines[€](#nt109){ref-type="table-fn"}                                                                                                                                                               Significant DNA-RNA Correlations[\#](#nt111){ref-type="table-fn"}                                                                                                                              Other notable genes[≠](#nt112){ref-type="table-fn"}
  ------------------- --------------- --------------- ----------- -------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------
  **AMPLIFICATION**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  1p32.2                 56946690        57156366         210                                                        EFM192A                                                                                                                                                                                                                                                                                                                                                                               
  1p22.1-1p21.3          93549298        97052934        3504                                         SUM44[\*](#nt110){ref-type="table-fn"}                                                                                                                                                                                   DR1, FNBP1L, ARHGAP29, ALG14                                                                                                                                                
  1p13.3                 107738670       109306637       1568                                                        HCC2688                                                                                                                                                                                              C1orf59, PRPF38B, STXBP3, GPSM2, CLCC1                                                                                                                                                                   VAV3
  1p13.2                 114220960       115183599        963                                                     MCF7, UACC812                                                                                                                                                                                    AP4B1, DCLRE1B, HIPK1, TRIM33, BCAS2, CSDE1, **NRAS**                                                                                                                                   
  1q21.2                 148738080       148885763        148                                                        HCC1143                                                                                                                                                                                                  TARS2, **MCL1**, ENSA, GOLPH3L                                                                                                                                               
  1q21.2-q21.3           149460307       150130540        670                                                    HCC712, UACC812                                                                                                                                                                                 PIP5K1A, PSMD4, ZNF687, PI4KB, PSMB4, POGZ, SNX27, MRPL9                                                                                                                                  
  1q21.3                 151000411       151885402        885                                                         HCC712                                                                                                                                                                                                                                                                                                                                                                               
  1q22                   153424958       153999982        575                                                        UACC812                                                                                                                                                                                  MUC1, C1orf2, CLK2, HCN3, PKLR, C1orf104, RUSC1, ASH1L, YY1AP1                                                                                                                               
  1q23.3                 159283361       159357995        75                                                          SUM190                                                                                                                                                                                                              KLHDC9                                                                                                                                                           
  1q32.1                 204736293       205144756        408                                                        UACC812                                                                                                                                                                                                             MAPKAPK2                                                                                                                                                                                  IKBKE
  3p14.2-p14.1           61765808        64574645        2809                                                          MCF7                                                                                                                                                                                                                                                                                                                                                                                
  3q26.32                178223920       180535525       2312                                                        HCC2185                                                                                                                                                                                                          TBL1XR1, ZNF639                                                                                                                                                                             PIK3CA
  3q29                   194971434       195513283        542                                                        HCC1937                                                                                                                                                                                                                                                                                                                                                                               
  3q29                   196883266       196931777        49                                                         HCC1937                                                                                                                                                                                                                                                                                                                                                                               
  4q12                   53304442        54084198         780                                                        HCC1007                                                                                                                                                                                                           SCFD2, FIP1L1                                                                                                                                                       
  5p15.33                 712977          2811691        2099                                                        HCC1954                                                                                                                                                                                                  ZDHHC11, PDCD6, MRPL36, NDUFS6                                                                                                                                                                       TERT
  6p12.1                 55358212        57236103        1878                                                        HCC1007                                                                                                                                                                                                      KIAA11586, ZNF451, BAG2                                                                                                                                                  
  6q16.3-q21             104858272       109112665       4254                                                        HCC2185                                                                                                                                                                                     HACE1, ATG5, C6orf203, PDSS2, SEC63, OSTM1, SNX3, FOXO3A                                                                                                                                  
  6q21-q22.31            111961945       123089199       11127                                                       HCC2185                                                                                                                                                                                      C6orf225, HDAC2, DSE, GOPC, NUS1, ASF1A, HSF2, SERINC1                                                                                                                                   
  7p15.2                 26557965        27107611         550                                                        HCC1007                                                                                                                                                                                                                                                                                                                                                                               
  7p11.2                 54595526        55931398        1336                                                      BT20, MDA468                                                                                                                                                                                                          **EGFR**                                                                                                                                                          
  7q21.13-q21.2          90779687        91868629        1089                                                         SUM52                                                                                                                                                                                                MTERF, AKAP9, CYP51A1, KRIT1, ANKIB1                                                                                                                                            
  7q21.3                 95239813        96489919        1250                                                         SUM52                                                                                                                                                                                                           SLC25A13, SHFM1                                                                                                                                                      
  7q22.1                 100294293       100421513        127                                                         SUM52                                                                                                                                                                                                               SLC12A9                                                                                                                                                          
  8p21.3                 21593811        21966432         373                                                         MDA134                                                                                                                                                                                                               XPO7                                                                                                                                                            
  8p12-p11.21            32328805        41907423        9579                     BT483, HCC1500, HCC1599, MDA134, SUM44[\*](#nt110){ref-type="table-fn"}, SUM52                                                                                        FUT10, C8orf41, MAK16, ZNF703, ERLIN2, PROSC, BRF2, RAB11FIP1, EIF4EBP1, ASH2L, LSM1, BAG4, DDHD2, WHSC1L1, LETM2, **FGFR1**, TACC1, PLEKHA2, TM2D2, ADAM9, GOLGA7, AGPAT6                                                                                                 IKBKB
  8q12.2-q12.3           61817956        62960675        1143                                                         SUM190                                                                                                                                                                                                               CHD7                                                                                                                                                            
  8q13.3                 71707355        72999610        1292                                                         SKBR3                                                                                                                                                                                                                                                                                                                                                                                
  8q21.11-q21.13         79781799        85260376        5479                                            EFM192A, HCC1419, HCC1599, SKBR3                                                                                                                                                                                           HEY1, TPD52, ZBTB10                                                                                                                                                    
  8q21.3-q22.1           89113344        95233478        6120                                                EFM192A, HCC1419, SKBR3                                                                                                                                                                                    OSGIN2, NBN, DECR1, OTUD6B, RBM12B, TMEM67                                                                                                                                         
  8q22.2-q22.3           100879473       101995283       1116                                                    HCC1419, HCC2185                                                                                                                                                                                                      COX6C, POLR2K                                                                                                                                                       
  8q22.3                 104311423       104550566        239                                                        HCC1419                                                                                                                                                                                                               FZD6                                                                                                                                                            
  8q23.1-q24.21          108267427       131134620       22867                                  EFM192A, HCC1419, HCC1599, HCC2185, SKBR3, ZR75-30                                                                                             EIF3E, TRPS1, EIF3H, C8orf53, RAD21, TAF2, DSCC1, MRPL13, MTBP, DERL1, WDR67, C8orf76, ZHX1, ATAD2, C8orf32, FAM91A1, TMEM65, TRMT12, RNF139, TATDN1, NDUFB9, SQLE, KIAA0196, NSMCE2, FAM84B                                                                                         MYC
  8q24.22                133917771       134337653        420                                                        ZR75-30                                                                                                                                                                                                              PHF20L1                                                                                                                                                          
  8q24.3                 141658961       143348731       1690                                                HCC1419, MDA436, ZR75-30                                                                                                                                                                                                 GPR20, FLJ43860                                                                                                                                                      
  8q24.3                 144310706       144753628        443                                                    MDA436, ZR75-30                                                                                                                                                                                         ZFP41, GLI4, ZNF696, C8orf51, RHPN1, MAFA                                                                                                                                         
  8q24.3                 145137850       146252219       1114                                            BT483, HCC1419, MDA436, ZR75-30                                                                                                                                                                    GRINA, OPLAH, SHARPIN, KIAA1833, FBXL6, CPSF1, VPS28, KIFC2, ZNF252                                                                                                                            
  9p13.3-p13.2           33876876        38058023        4181                                                        HCC2185                                                                                                  UBE2R2, UBAP2, WDR40A, KIF24, KIAA1161, DCTN3, GALT, IL11RA, VCP, FANCG, PIGO, STOML2, RUSC2, TESK1, CD72, C9orf100, TLN1, CREB3, RGP1, HINT2, CLTA, RNF38, MELK, ZCCHC7, GRHPR, ZBTB5, POLR1E, FBXO10, RG9MTD3, WDR32, MCART1                                               
  9q33.3                 128307884       129195638        888                                         SUM44[\*](#nt110){ref-type="table-fn"}                                                                                                                                                                                              RALGPS1                                                                                                                                                          
  10q21.1-q21.2          72507196        73797267        1290                                                        HCC2157                                                                                                                                                                                                              DNAJB12                                                                                                                                                          
  10q22.2-q22.3          76461776        82106491        5645                                                     EFM19, HCC2157                                                                                                                                                                SAMD8, VDAC2, DLG5, POLR3A, RPS24, LOC283050, ZMIZ1, PPIF, SFTPA1, FAM22E, C10orf57, ANXA11                                                                                                                
  10q24.33-q25.1         105307581       106054698        747                                                         EFM19                                                                                                                                                                                                              SH3PXD2A                                                                                                                                                          
  10q26.13               124598599       124962466        364                                                         SUM52                                                                                                                                                                                                             IKZF5, BUB3                                                                                                                                                        
  11p13                  33062705        35600197        2537                                        HCC1806[\*](#nt110){ref-type="table-fn"}                                                                                                                                                                   HIPK3, FBXO3, CAPRIN1, NAT10, ABTB2, CAT, APIP, PDHX, CD44                                                                                                                                 
  11q13.2                66874536        67198753         324                                                     MDA134, ZR75-1                                                                                                                                                                                              RAD9A, RPS6KB2, CORO1B, TMEM134                                                                                                                                              
  11q13.3-q13.4          68427956        70812048        2384           HCC1143, HCC1500, HCC1954, MDA134, MDA175, MDA361, SUM44[\*](#nt110){ref-type="table-fn"}, SUM190,                                                                                                                                                  IGHMBP2, FADD, PPFIA1, CTTN, SHANK2                                                                                                                                                                    CCND1
  11q13.4                73316198        73649077         333                                                 BT474, MDA134, SUM190                                                                                                                                                                                                 UCP2, C2CD3, PPME1                                                                                                                                                     
  11q13.4-q14.1          74648813        77963474        3315                             MDA134, SUM44[\*](#nt110){ref-type="table-fn"}, SUM52, SUM190                                                                                                                                       ARRB1, PRKRIR, **EMSY**, PHCA, PAK1, AQP11, CLNS1A, C11orf67, INTS4, NDUFC2, ALG8, GAB2, NARS2                                                                                                               
  12p12.3                18727378        19246201         519                                                        HCC1500                                                                                                                                                                                                                                                                                                                                                                               
  12q21.31-q21.33        88265969        88443930         178                                                         SUM52                                                                                                                                                                                                           WDR51B, GALNT4                                                                                                                                                       
  13q22.2-q31.1          74756931        78096263        3339                                                        UACC812                                                                                                                                                                                                               UCHL3                                                                                                                                                           
  13q31.3-q32.1          90798074        93942902        3145                                                        UACC812                                                                                                                                                                                                                                                                                                                                                                               
  16q12.2                51800892        53524601        1724                                     EFM19, SUM44[\*](#nt110){ref-type="table-fn"}                                                                                                                                                                                          CHD9, FTO                                                                                                                                                         
  17p12                  12611513        13636592        1025                                                        EFM192A                                                                                                                                                                                                               ELAC2                                                                                                                                                           
  17q11.2                23686912        24013273         326                                                        ZR75-30                                                                                                                                                                                 POLDIP2, TREM199, SLC46A1, PIGS, SPAG5, FLJ25006, KIAA0100, SDF2                                                                                                                              
  17q11.2                24894649        25818484         924                                                         HCC202                                                                                                                                                                                               TAOK1, LOC116236, GIT1, ANKRD13B, CPD                                                                                                                                           
  17q11.2                27727543        28293356         566                                                         SUM190                                                                                                                                                                                                              ZNF207                                                                                                                                                           
  17q12                  31206068        31649844         444                                                         MDA361                                                                                                                                                                                                             FLJ12120                                                                                                                                                          
  17q12-q21.2            32627885        36209712        3582      BT474, EFM192A, HCC202, HCC1419, HCC1569, HCC1954, HCC2218, MDA361, SKBR3, SUM190, UACC812, UACC893, ZR75-30                           ACACA, TADA2L, DDX52, SOCS7, MLLT6, CISD3, PCGF2, PSMB3, PIP4K2B, CCDC49, RPL23, LASP1, CACNB1, FAM153C, RPL19, LOC90110, FBXL20, MED1, PPP1R1B, STARD3, TCAP, PERLD1, **ERBB2**, C17orf37, GRB7, IKZF3, GSDML, ORMDL3, PSMD3, MED24, MSL-1, CASC3, CDC6, RARA, SMARCE1                          
  17q21.31               38419019        38738864         320                                                         SUM190                                                                                                                                                                                                               RND2                                                                                                                                                            
  17q21.32-q25.1         43329972        50826668        7497                               BT474, EFM192A, HCC202, HCC712, HCC1419, HCC2218, ZR75-30                                                                     SP2, PNPO, CDK5RAP3, SNX11, HOXB13, CALCOCO2, ATP5G1, UBE2Z, SNF8, ZNF652, PHB, SPOP, SLC35B1, FAM117A, MYST2, PDK2, XYLT2, MRPL27, LRRC59, EME1, ACSF2, RSAD1, EPN3, SPATA20, ABCC3, ANKRD40, CROP, TOB1, NME1, TOM1L1, COX11, STXBP4                                           
  17q23.2-q24.2          53282667        63106134        9823                                     BT474, HCC712, HCC2218, MCF7, MDA361, ZR75-30                                   SFRS1, DYNLL2, MKS1, SUPT4H1, MTMR4, RAD51C, TRIM37, FAM33A, C17orf71, YPEL2, DHX40, CLTC, PTRH2, TMEM49, TUBD1, **RPS6KB1**, RNFT1, HEATR6, USP32, APPBP2, **PPM1D**, BRIP1, INTS2, MED13, METTL2A, TLK2, TANC2, CYB561, WDR68, CCDC44, MAP3K3, LYK5, CCDC47, DDX42, PSMC5, SMARCD2, DDX5, CCDC45, SMURF2, GNA13, HELZ  
  17q25.1                69755691        71418122        1662                                            HCC2218, MDA361, MDA453, UACC893                                                                                                               GPRC5C, SLC9A3R1, NAT9, TMEM104, FDXR, C17orf28, CDR2L, ICT1, KCTD2, SUMO2, NUP85, GGA3, MRPS7, MIF4GD, SLC25A19, GRB2, CASKIN2, TSEN54, MYO15B, SAP30BP, H3F3B, UNK, WBP2                                                                         
  18q21.32-q21.33        55178911        57628085        2449                                                        HCC1500                                                                                                                                                                                                                                                                                                                                                                               
  19p13.2                14932742        15602448         670                                                        HCC1143                                                                                                                                                                                                        ILVBL, BRD4, AKAP8L                                                                                                                                                    
  19q12-q13.11           33966349        38052482        4086                                                    HCC1569, HCC1599                                                                                                                                                                                    UQCRFS1, POP4, PLEKHF1, C19orf2, DPY19L3, ANKRD27                                                                                                                                     
  19q13.11               39866832        40146793         280                                                        HCC1599                                                                                                                                                                                                                                                                                                                                                                               
  19q13.42               60551045        60898029         347                                                         EFM19                                                                                                                                                                                                        FIZ1, ZNF784, CCDC106                                                                                                                                                   
  19q13.43               63208125        63774724         567                                        HCC1806[\*](#nt110){ref-type="table-fn"}                                                                                                                                                                  ZNF329, ZNF274, ZNF8, ZSCAN22, ZNF324, TRIM28, CHMP2A, UBE2M                                                                                                                                
  20p12.2                10224083        10433564         209                                                        HCC2185                                                                                                                                                                                                               MKKS                                                                                                                                                            
  20q11.22               32363269        33563203        1200                                                         BT474                                                                                                                                                                                                        DYNLRB1, NCOA6, UQCC                                                                                                                                                    
  20q13.12               42493067        43286511         793                                                      BT474, SUM52                                                                                                                                                                                                           SERINC3                                                                                                                                                          
  20q13.12-q13.13        45234836        48636574        3402                                                  BT474, HCC1419, MCF7                                                                                                                                                                          NCOA3, PREX1, ARFGEF2, STAU1, DDX27, ZNFX1, SLC9A8, SPATA2, PTPN1                                                                                                                             
  20q13.13-q13.32        49139330        57334442        8195                                              BT474, HCC1419, MCF7, SKBR3                                                                                                                                 ZFP64, **ZNF217**, BCAS1, PFDN4, C20orf108, CSTF1, C20orf43, TFAP2C, BMP7, RAE1, RBM38, RAB22A, VAPB, STX16, NPEPL1, GNAS, TH1L, ATP5E, SLMO2                                                                                                               AURKA
  20q13.33               61801252        62370522         569                                                        HCC1419                                                                                                                                                                                                           PRR17, OPRL1                                                                                                                                                        
  22q11.21               18256420        19686015        1430                                                         SUM190                                                                                                                                                                                                        COMT, HTF9C, PI4KA                                                                                                                                                     
  22q12.1                24895479        25885840         990                                                         HCC202                                                                                                                                                                                                               HPS4                                                                                                                                                            
  Xp11.23-p11.22         48635684        51225253        2590                                                         HCC712                                                                                                                                                                                                                                                                                                                                                                               
  Xp11.22                52255712        54236019        1980                                                         HCC202                                                                                                                                                                                                           TMEM29, PHF8                                                                                                                                                        
  Xq28                   148368959       149592006       1223                                                         HCC202                                                                                                                                                                                                                                                                                                                                                                               
  **DELETION**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  6q16.3-q21             102493055       105832848       3340                                                        HCC1395                                                                                                                                                                                                             **HACE1**                                                                                                                                                         
  7q11.23-q21.11         77246720        77484743         238                                        HCC1806[\*](#nt110){ref-type="table-fn"}                                                                                                                                                                                          TMEM60, PHTF2                                                                                                                                                       
  8p23.3                  604200          2080787        1477                                                        HCC2688                                                                                                                                                                                                              ERICH1                                                                                                                                                           
  9p24.3-p24.2            958704          3213008        2254                                                        HCC2185                                                                                                                                                                                                          VLDLR, KIAA0020                                                                                                                                                      
  9p21.2-p21.1           26894518        29207861        2313                                                      BT474, EFM19                                                                                                                                                                                                         PLAA, IFT74                                                                                                                                                                               CDKN2A
  13q14.3-13q21.2        52175620        60001053        7825                                                        HCC1395                                                                                                                                                                                                                                                                                                                                                                               
  15q24.3                74984799        75116728         132                                        HCC1806[\*](#nt110){ref-type="table-fn"}                                                                                                                                                                                              RCN2                                                                                                                                                            
  17p12                  11405197        11987872         583                                                         EFM19                                                                                                                                                                                                               MAP2K4                                                                                                                                                           
  17q21.31               38252285        38419019         167                                        HCC1806[\*](#nt110){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                                                                                      BRCA1
  18q11.2-q12.1          22256956        23913060        1656                                                        HCC2185                                                                                                                                                                                                                                                                                                                                                                               
  21q21.1                18342236        21590772        3249                                                        ZR75-30                                                                                                                                                                                                                                                                                                                                                                               
  Xp11.3                 46208136        46345060         137                                                        HCC2157                                                                                                                                                                                                                                                                                                                                                                               
  Xq25                   122657657       123338533        681                                        HCC1806[\*](#nt110){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                                                              

For aberrations spanning multiple lines, inclusive interval indicated.

DNA but not RNA profiled.

Only named genes listed, ordered by genome position; bold text indicates select known cancer genes.

Within or immediately flanking interval.

Discussion {#s4}
==========

Using whole-genome DNA microarrays, we collected transcriptional and genomic profiles across a set of 52 widely used breast cancer cell lines, with the primary goals to establish their suitability in modeling known breast tumor heterogeneity, and to create a resource for cancer gene discovery. Cluster analysis of transcriptional profiles defined three cell line subtypes, one luminal and two basal (A and B), consistent with other recent studies of breast cancer cell lines [@pone.0006146-CharafeJauffret1], [@pone.0006146-Neve1], [@pone.0006146-Ross1]. The luminal subtype included all ER-positive cell lines, and associated gene expression patterns reflected both ER and luminal differentiation pathways, the latter including GATA3 and FOXA1, key transcriptional mediators of luminal differentiation [@pone.0006146-KourosMehr1], [@pone.0006146-AsselinLabat1]. The basal-like cell lines were ER-negative and exhibited more frequent mutations of *TP53* and *PTEN*, consistent with findings in basal-like tumors [@pone.0006146-Sorlie1], [@pone.0006146-Saal1]. The basal-A subtype exhibited enriched expression of ETS pathway genes, a pathway linked to diverse tumor phenotypes including invasion and metastasis [@pone.0006146-Oikawa1]. The basal-B subtype, which included the three non-tumorigenic lines (consistent with prior studies [@pone.0006146-Ross1]), as well as five highly invasive/metastatic lines with features of EMT, exhibited enriched expression of EMT and EGF regulated genes, the latter pathway also previously linked to basal-like tumors [@pone.0006146-Livasy1].

Recently, Neve *et al*. [@pone.0006146-Neve1] profiled 51 breast cancer cell lines (though using a lower-resolution (∼1 Mb) CGH platform), 38 of which (∼3/4^th^) overlapped with the 52 we profiled. All the overlapping lines except for one clustered into the same corresponding gene-expression subtype in both their and our study. The exception was HCC1500, which we classified as luminal while Neve *et al*. labeled it as basal B. The discrepancy may reflect a cell line identification error. We note that ATCC describes the line as ER-positive, more consistent with a luminal classification.

Our comparisons of expression profiles between breast cancer cell line subtypes and breast tumor subtypes provided valuable information relevant to the suitability of cell lines in modeling known breast tumor heterogeneity. Luminal-A/B tumors best matched luminal cell lines. Notably, basal-like tumors most corresponded to basal-A cell lines. Consistent with this finding, two breast cancer cell lines from *BRCA1* mutation carriers also clustered in basal-A (and basal-A lines exhibited enrichment of a BRCA1 signature), where it has been established that *BRCA1*-associated tumors share many features with sporadic basal-like tumors [@pone.0006146-Turner1]. Interestingly, ERBB2-associated tumors matched both luminal and basal-A lines. While ERBB2 represents a distinct expression tumor subtype in multiple independent cohorts [@pone.0006146-Sorlie1], [@pone.0006146-Sorlie2], [@pone.0006146-Sotiriou1], it is noteworthy that most ERBB2 (HER2+) cell lines clustered in the luminal subtype. The basis for the discrepant ERBB2 grouping in cell lines and tumors is unclear but warrants further investigation.

It has been suggested that the origin of the luminal *vs*. basal breast cancer distinction reflects the transformation of different breast epithelial progenitor cell compartments [@pone.0006146-Dontu1], [@pone.0006146-Sims1]. Breast epithelial stem/progenitor cells support mammary gland development during puberty and subsequent growth and remodeling during pregnancy [@pone.0006146-Molyneux1]. A prevailing view is that breast epithelial stem cells give rise to bipotent basal/luminal progenitors, which then give rise to basal and luminal restricted progenitors, and from there to differentiated basal/myoepithelial and luminal epithelial cells [@pone.0006146-Molyneux1], [@pone.0006146-Polyak1]. Bipotent human breast epithelial stem/progenitors have been characterized with the cell surface phenotype MUC^−/low^/CALLA^low/+^ [@pone.0006146-Stingl1]. Separately, breast cancer stem cells, identified prospectively as tumor initiating cells when transplanted into immunodeficient mice, have been characterized by the surface expression phenotype CD44^+^/CD24^−/low^ [@pone.0006146-AlHajj1], also a presumed phenotype of normal breast epithelial stem or early progenitor cells [@pone.0006146-Molyneux1].

Our transcriptional profiles of breast cancer cell lines are consistent with an origin in (or at least a likeness of the bulk cell population to) the various stem/progenitor cell compartments. Basal-B lines predominantly express CD44^+^/CD24^−/low^ and MUC^−^/CALLA^+^ phenotypes characteristic of stem or bipotent progenitor cells, as well as ITGB3 (CD61), also recently characterized as a cancer stem cell marker in MMTV-wnt-1 induced murine breast cancer [@pone.0006146-Vaillant1]. In contrast, basal-A lines appear mainly CD44^+^/CD24^+^, but express PROM1 (aka CD133), a marker of luminal progenitors in mice [@pone.0006146-Sleeman1] also more recently characterized as a stem cell marker in BRCA1-associated breast cancer [@pone.0006146-Wright1], while luminal lines express markers of luminal lineage restriction like GATA3 and FOXA1 [@pone.0006146-KourosMehr1]. Conspicuously absent from our analysis is a breast tumor subtype corresponding to the stem-cell like (and sometimes mesenchymal-like) basal-B lines. Whether basal-B lines reflect an uncommon tumor subtype not yet characterized, or else a stem/progenitor subpopulation of tumor cells enriched in culture, or even an artifact of cell culture, remains to be determined. Regardless, breast cancer cell lines are likely to prove useful for discovering new stem cell markers, and for studying stem/progenitor cell biology.

Our genomic profiles of breast cancer cell lines indicate that overall the spectra of CNAs is reflective of breast tumors, consistent with prior findings from loss of heterozygosity (LOH) analysis [@pone.0006146-Wistuba1]. Overall, however, cell lines exhibited higher frequencies and greater complexities of CNAs, and seemingly more than might be explained by a higher sensitivity of detecting CNAs in stromal-free tumor cell populations. Notably absent among the luminal subtype were the "simple" karyotypes characteristic of luminal-A tumors (i.e. 1q+, 16p+/16q−). By genomic profiles, luminal cell lines shared features characteristic of luminal-B tumors, including certain subtype-specific CNAs and overall higher levels of DNA amplification. Likewise, basal-A cell lines and basal-like tumors shared the feature of high levels of chromosome segment gain/loss. However, overall only a subset of subtype-specific CNAs was preserved. Therefore, at the genomic level it is uncertain how well cell line subtypes faithfully represent tumor subtype counterparts.

Taken together, the transcriptional and genomic profiles support the conclusion that luminal and basal-A cell lines are the most appropriate cell line models of luminal-B and basal-like tumors, respectively. Further, the basal lines are likely useful models for biological studies of the 70-gene, wound and hypoxia signatures. Despite incongruent expression results, luminal lines with amplification/overexpression of ERBB2 are likely appropriate models of ERBB2-associated tumors. Our findings indicate that new cell lines are needed to more faithfully model luminal-A tumors. Currently available cell lines likely reflect certain biases in the specimen source of cell line, and/or in the culturing methods, as suggested by the predominance of HCC lines (from UT Southwestern) among the basal-A group. Different culturing methods (e.g. ref. [@pone.0006146-Ince1]) might support the establishment of cell lines from luminal-A tumors.

Our genomic profiles also identified numerous high-level DNA amplifications and multi-copy deletions, pinpointing known and novel cancer genes. Further, by integrating the genomic and transcriptional datasets, we could define a set of candidate cancer genes residing at these loci and exhibiting both altered copy number and expression. The larger set of amplified/overexpressed genes included several known breast cancer oncogenes, as well as many plausible candidates including genes with known functions relevant to carcinogenesis, like cell proliferation, survival and motility/invasion, and genome integrity (e.g. DNA damage response). Though genes maintaining genome integrity are more typically considered candidate tumor suppressors, the overexpression of such genes has been linked to genome instability [@pone.0006146-Hauf1], [@pone.0006146-Richardson1]. The set of amplified/overexpressed genes also included many druggable targets [@pone.0006146-Hopkins1], most notably several kinases. Importantly, the same cell lines used for discovery can also be used to functionally examine cancer gene candidates, for example using RNA interference to knockdown the expression of amplified oncogene candidates, and then assaying loss of tumorigenic phenotypes in cultured cells or *in vivo* (e.g. refs.[@pone.0006146-Kao1], [@pone.0006146-Streicher1]). Indeed, high-throughput RNA interference approaches [@pone.0006146-Hannon1], [@pone.0006146-Silva1] might be used to evaluate many or all of the candidate cancer genes simultaneously.

In summary, transcriptional and genomic profiling of 52 commonly used breast cancer cell lines identifies cell line subtypes, and defines the cell line subtypes that most faithfully capture the known heterogeneity of breast tumors. Specifically, luminal and basal-A lines appear to best model the features of luminal-B and basal-like tumors, while basal-B lines might inform stem cell biology. In addition, our integrated analysis of genomic and transcriptional profiles pinpoints loci and genes with altered copy number and expression, providing a rich source for discovery and future characterization of new breast cancer genes.
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